AR057252A1 - Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares - Google Patents

Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares

Info

Publication number
AR057252A1
AR057252A1 ARP060105556A ARP060105556A AR057252A1 AR 057252 A1 AR057252 A1 AR 057252A1 AR P060105556 A ARP060105556 A AR P060105556A AR P060105556 A ARP060105556 A AR P060105556A AR 057252 A1 AR057252 A1 AR 057252A1
Authority
AR
Argentina
Prior art keywords
rho kinase
inhibition
treatment
arni
eye disorders
Prior art date
Application number
ARP060105556A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR057252A1 publication Critical patent/AR057252A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se provee interferencia por ARN para la inhibicion de la expresion del ARNm de la Rho quinasa para tratar pacientes con trastornos oculares, en particular para el tratamiento de la presion intraocular, hipertension ocular y glaucoma. Los blancos del ARNm de Rho quinasa incluyen el ARNm para ROCK1 y ROCK2.
ARP060105556A 2005-12-27 2006-12-15 Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares AR057252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75409405P 2005-12-27 2005-12-27

Publications (1)

Publication Number Publication Date
AR057252A1 true AR057252A1 (es) 2007-11-21

Family

ID=38218805

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105556A AR057252A1 (es) 2005-12-27 2006-12-15 Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares

Country Status (14)

Country Link
US (4) US20070149473A1 (es)
EP (2) EP2592144A1 (es)
JP (2) JP2009532325A (es)
KR (1) KR20080079264A (es)
CN (1) CN101326285A (es)
AR (1) AR057252A1 (es)
AU (1) AU2006330606A1 (es)
BR (1) BRPI0621264A2 (es)
CA (2) CA2821393A1 (es)
RU (2) RU2432165C2 (es)
TW (1) TW200731979A (es)
UY (1) UY30060A1 (es)
WO (1) WO2007076367A2 (es)
ZA (1) ZA200805599B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
BRPI0817937A2 (pt) * 2007-10-01 2015-04-07 Alcon Res Ltd Entrega mediada por aav autocomplementar de moléculas de rna de interferência para tratar ou prevenir distúrbios oculares
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
AR069328A1 (es) 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
PT3124610T (pt) * 2010-10-28 2019-06-14 Benitec Biopharma Ltd Tratamento do vhb
CN102343091A (zh) * 2011-03-01 2012-02-08 中国科学技术大学 一种基于ezrin磷酸化的物质及其应用
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
US20130178421A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
CN111471653B (zh) * 2017-03-01 2022-11-25 中国科学院动物研究所 一种将非神经元细胞转化为神经元细胞的方法
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CA3232251A1 (en) 2021-09-30 2023-04-06 Regeneron Pharamaceuticals, Inc. Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors
AU2023283348A1 (en) 2022-06-07 2025-01-09 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20050222029A1 (en) * 2001-01-04 2005-10-06 Myriad Genetics, Incorporated Compositions and methods for treating diseases
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US20050019746A1 (en) * 2003-01-23 2005-01-27 Eirx Therapeutics Limited Apoptosis-related kinase/GPCRs
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
AU2003300239A1 (en) * 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005085466A2 (en) * 2004-03-09 2005-09-15 Bayer Healtcare Ag Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005085469A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions

Also Published As

Publication number Publication date
US20090275641A1 (en) 2009-11-05
EP2592144A1 (en) 2013-05-15
JP2009532325A (ja) 2009-09-10
WO2007076367A2 (en) 2007-07-05
UY30060A1 (es) 2007-04-30
RU2008130855A (ru) 2010-02-10
US20070149473A1 (en) 2007-06-28
WO2007076367A3 (en) 2008-04-17
BRPI0621264A2 (pt) 2011-12-06
RU2432165C2 (ru) 2011-10-27
CA2821393A1 (en) 2007-07-05
RU2011124528A (ru) 2012-12-27
CA2631840A1 (en) 2007-07-05
US20120178794A1 (en) 2012-07-12
AU2006330606A1 (en) 2007-07-05
TW200731979A (en) 2007-09-01
JP2012193210A (ja) 2012-10-11
US8168609B2 (en) 2012-05-01
CN101326285A (zh) 2008-12-17
ZA200805599B (en) 2009-11-25
US20110245319A1 (en) 2011-10-06
KR20080079264A (ko) 2008-08-29
EP1989305A2 (en) 2008-11-12

Similar Documents

Publication Publication Date Title
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2020010469A (es) Inhibidores del atf6 y sus usos.
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
UY29348A1 (es) Inhibición de objetivos oculares mediada por arni
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
DOP2012000025A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
CL2008002294A1 (es) Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer.
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
UY30061A1 (es) Inhibición de hif 1a mediada por arni para el tratamiento de la angiogénesis ocular
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
MX2018003542A (es) Metodos para tratar presion intraocular con activadores de tie-2.
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
AR067395A1 (es) Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
GT200500316A (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112012015386B8 (pt) composição oftálmica tópica
AR067786A1 (es) Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
UY29627A1 (es) Derivados de prostaglandina
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma

Legal Events

Date Code Title Description
FB Suspension of granting procedure